Horizon Pharma Shares Plunge on Failed Late-Stage Study

Horizon Pharma shares slid 20% after a late-stage study for a genetic disease treatment broadly failed testing.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: PAID Source Type: news